Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Research

Pulmonary embolism in non-brain tumor patients after surgery—a retrospective study in China

Authors: Ren-Xiong Chen, Hong-Zhi Wang, Jun Dong, Hong Ren, Xiao-Jie Chen, Jia-Xuan Xu, Yong Yang, Guo-Dong Wang

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

The incidence rate of pulmonary emboli (PE) is high in tumor patients; however, the morbidity and mortality associated with the development of PE after tumor surgery are unknown. We studied the clinical profiles and outcomes of patients with PE after non-brain tumor surgery.

Methods

We retrospectively screened 55,967 patients who underwent non-brain tumor surgery at the Peking University Cancer Hospital from January 2008 to June 2015. Among them, 76 patients who were diagnosed with PE were enrolled in our study. Factors impacting the overall survival at 90 days were analyzed. A Kaplan-Meier curve was plotted for time to death or until day 90. Cox proportional hazard modeling was performed for univariate- and multivariate-adjusted factor analyses.

Results

The morbidity rate was approximately 135.8 per 100,000 non-brain tumor surgery patients (possibly underestimated). When treated, seven patients had major bleeding, and 14 patients had clinically relevant non-major bleeding, which represented 9.2 and 18.4% of all the patients, respectively. The 3-month overall mortality rate was 11.8% in our study. The Acute Physiology and Chronic Health Evaluation II (APACHE II) score and platelet distribution width (PDW) were independent risk factors for the prognosis of PE after non-brain surgery (P values of 0.001 and 0.016, respectively).

Conclusions

Treatment of PE in non-brain tumor surgical patients remained a challenge due to the high bleeding rate. The APACHE II score and PDW were independent prognostic factors of survival in patients with PE after non-brain tumor surgery; however, the study power was limited.
Literature
4.
go back to reference Heit JA, Cohen AT, Anderson FA, OBOIA Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005;106:267A. Heit JA, Cohen AT, Anderson FA, OBOIA Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005;106:267A.
9.
go back to reference Sweetland S, Green J, Liu B, Berrington de González A, Canonico M, Reeves G, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009;339:b4583.CrossRefPubMedPubMedCentral Sweetland S, Green J, Liu B, Berrington de González A, Canonico M, Reeves G, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009;339:b4583.CrossRefPubMedPubMedCentral
13.
go back to reference Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O’Neil BJ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J am coll cardiol. 2011;57:700–6. doi:10.1016/j.jacc.2010.05.071.CrossRefPubMed Pollack CV, Schreiber D, Goldhaber SZ, Slattery D, Fanikos J, O’Neil BJ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J am coll cardiol. 2011;57:700–6. doi:10.​1016/​j.​jacc.​2010.​05.​071.CrossRefPubMed
15.
go back to reference Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e227S–77S. doi:10.1378/chest.11-2297.CrossRefPubMedPubMedCentral Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e227S–77S. doi:10.​1378/​chest.​11-2297.CrossRefPubMedPubMedCentral
16.
go back to reference Muriel A, Jiménez D, Aujesky D, Bertoletti L, Decousus H, Laporte S, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J am coll cardiol. 2014;63:1675–83. doi:10.1016/j.jacc.2014.01.058.CrossRefPubMed Muriel A, Jiménez D, Aujesky D, Bertoletti L, Decousus H, Laporte S, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J am coll cardiol. 2014;63:1675–83. doi:10.​1016/​j.​jacc.​2014.​01.​058.CrossRefPubMed
20.
21.
go back to reference Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Pulmonaire. N engl j med. 1997;337:663–9. doi:10.1056/NEJM199709043371002.CrossRefPubMed Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l’Embolie Pulmonaire. N engl j med. 1997;337:663–9. doi:10.​1056/​NEJM199709043371​002.CrossRefPubMed
23.
go back to reference Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N engl j med. 2003;349:1695–702. doi:10.1056/NEJMoa035451.CrossRefPubMed Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N engl j med. 2003;349:1695–702. doi:10.​1056/​NEJMoa035451.CrossRefPubMed
26.
go back to reference Yardan T, Meric M, Kati C, Celenk Y, Atici A. Mean platelet volume and mean platelet volume/platelet count ratio in risk stratification of pulmonary embolism. Crit care. 2015;19 Suppl 1:328. doi:10.1186/cc14408.CrossRef Yardan T, Meric M, Kati C, Celenk Y, Atici A. Mean platelet volume and mean platelet volume/platelet count ratio in risk stratification of pulmonary embolism. Crit care. 2015;19 Suppl 1:328. doi:10.​1186/​cc14408.CrossRef
27.
go back to reference Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N engl j med. 2003;349:146–53. doi:10.1056/NEJMoa025313.CrossRefPubMed Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N engl j med. 2003;349:146–53. doi:10.​1056/​NEJMoa025313.CrossRefPubMed
28.
30.
go back to reference EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N engl j med. 2012;366:1287–97. doi:10.1056/NEJMoa1113572.CrossRef EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N engl j med. 2012;366:1287–97. doi:10.​1056/​NEJMoa1113572.CrossRef
31.
go back to reference Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15. doi:10.1056/NEJMoa1306638.CrossRef Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15. doi:10.​1056/​NEJMoa1306638.CrossRef
Metadata
Title
Pulmonary embolism in non-brain tumor patients after surgery—a retrospective study in China
Authors
Ren-Xiong Chen
Hong-Zhi Wang
Jun Dong
Hong Ren
Xiao-Jie Chen
Jia-Xuan Xu
Yong Yang
Guo-Dong Wang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-016-1074-3

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue